ATORVASTATIN CALCIUM tablet, film coated

Land: Bandaríkin

Tungumál: enska

Heimild: NLM (National Library of Medicine)

Virkt innihaldsefni:

ATORVASTATIN CALCIUM TRIHYDRATE (UNII: 48A5M73Z4Q) (ATORVASTATIN - UNII:A0JWA85V8F)

Fáanlegur frá:

Preferred Pharmaceuticals Inc.

INN (Alþjóðlegt nafn):

ATORVASTATIN CALCIUM TRIHYDRATE

Samsetning:

ATORVASTATIN 10 mg

Stjórnsýsluleið:

ORAL

Gerð lyfseðils:

PRESCRIPTION DRUG

Ábendingar:

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin

Vörulýsing:

Atorvastatin Calcium Tablets are supplied as white, round, film-coated tablets of atorvastatin calcium containing 10, 20, 40, and 80 mg atorvastatin. 10 mg tablets: debossed with "1" on one side and plain on the other.  NDC 68788-6862-3  NDC 68788-6862-6  NDC 68788-6862-9  NDC 68788-6862-1  bottles of 30  bottles of 60  bottles of 90  bottles of 100 Storage Store at controlled room temperature 20 - 25°C (68 - 77°F) [see USP].

Leyfisstaða:

Abbreviated New Drug Application

Vara einkenni

ATORVASTATIN CALCIUM- ATORVASTATIN CALCIUM TABLET, FILM COATED
PREFERRED PHARMACEUTICALS INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
ATORVASTATIN CALCIUM TABLETS
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
ATORVASTATIN CALCIUM TABLETS.
ATORVASTATIN CALCIUM TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1996
RECENT MAJOR CHANGES
Dosage and Administration, Dosage in Patients Taking Cyclosporine,
Clarithromycin, Itraconazole, or Certain Protease
Inhibitors (2.6) 04/2019
Warnings and Precautions, Skeletal Muscle
(5.1) 04/2019
INDICATIONS AND USAGE
Atorvastatin calcium tablets are an HMG-CoA reductase inhibitor
indicated as an adjunct therapy to diet to:
•
•
•
•
•
•
•
Limitations of Use:
Atorvastatin calcium tablets have not been studied in _Fredrickson_
Types I and V dyslipidemias (1.3).
DOSAGE AND ADMINISTRATION
•
•
•
•
DOSAGE FORMS AND STRENGTHS
Tablets: 10, 20, 40, and 80 mg of atorvastatin (3).
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
Reduce the risk of MI, stroke, revascularization procedures, and
angina in adult patients without CHD, but with
multiple risk factors (1.1).
Reduce the risk of MI and stroke in adult patients with type 2
diabetes without CHD, but with multiple risk factors
(1.1).
Reduce the risk of non-fatal MI, fatal and non-fatal stroke,
revascularization procedures, hospitalization for CHF, and
angina in adult patients with CHD (1.1).
Reduce elevated total-C, LDL-C, apo B, and TG levels and increase
HDL-C in adult patients with primary
hyperlipidemia (heterozygous familial and nonfamilial) and mixed
dyslipidemia (1.2).
Reduce elevated TG in adult patients with hypertriglyceridemia and
primary dysbetalipoproteinemia (1.2).
Reduce total-C and LDL-C in patients with homozygous familial
hypercholesterolemia (HoFH) (1.2).
Reduce elevated total-C, LDL-C, and apo B levels in pediatric
patients, 10 years to 17 years of age, with heterozygous
familial hypercholesterolemia (HeFH) after failing